Inovio Pharmaceuticals Return on Equity

Inovio Pharmaceuticals (INO) currently reports a ROE of -1399.93%. That is below the Industrials sector average of 22.29%. Use the charts on this page to explore Inovio Pharmaceuticals's ROE history and peer comparisons.

Inovio Pharmaceuticals's ROE of -1399.93% is lower than the Industrials sector average of 22.29%. That is roughly 6379.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Inovio Pharmaceuticals's current -1399.93% should be judged against Industrials norms (sector average: 22.29%) and against INO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -1399.93%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Industrials average is 22.29%. From there, open related valuation or income-statement pages for Inovio Pharmaceuticals, and consider following INO for alerts when major investors trade the stock.

Inovio Pharmaceuticals is classified in the Industrials sector. On ROE, it currently shows -1399.93% versus a sector average near 22.29%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Industrials are usually more informative than comparing INO with unrelated industries.